

## Datasheet for ABIN1703782

## anti-DOK7 antibody (AA 21-120) (Cy5)



## Overview

Alternative Name:

| Quantity:             | 100 μL   |
|-----------------------|--|
| Target:               | DOK7   |
| Binding Specificity:  | AA 21-120  |
| Reactivity:           | Rat  |
| Host:                 | Rabbit   |
| Clonality:            | Polyclonal   |
| Conjugate:            | This DOK7 antibody is conjugated to Cy5  |
| Application:          | Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence |
|                       | (Paraffin-embedded Sections) (IF (p))  |
| Product Details       |  |
| Immunogen:            | KLH conjugated synthetic peptide derived from human DOK7                                 |
| Isotype:              | IgG  |
| Cross-Reactivity:     | Rat  |
| Predicted Reactivity: | Human,Mouse,Dog,Cow,Sheep,Pig,Horse  |
| Purification:         | Purified by Protein A.   |
| Target Details        |  |
| Target:               | DOK7   |
| Ali e Al              | DOVZ (DOVZ D )   |

DOK7 (DOK7 Products)

## **Target Details**

| Background:         | Synonyms: Docking protein 7, DOK 7, DOK7, DOK7_HUMAN, Downstream of tyrosine kinase 7,           |
|---------------------|--|
|                     | Protein Dok-7.   |
|                     | Background: The downstream of kinase family (Dok1-7) are members of a class of docking?          |
|                     | proteins that include the tyrosine kinase substrates IRS-1 and Cas, which contain multiple       |
|                     | tyrosine residues and putative SH2 binding sites. Based on their similarities, the Dok family of |
|                     | proteins can be divided into three subgroups: Dok-1/2/3, Dok-4/5/6 and Dok-7. Through its        |
|                     | interaction with muscle-specific receptor kinase (MuSK), Dok-7 is crucial for neuromuscular      |
|                     |  |
|                     | synaptogenesis and for MuSK activation. Mice lacking Dok-7 do not form neuromuscular             |
|                     | synapses nor acetylcholine receptor clusters. Mutations in the Dok-7 gene can cause              |
|                     | congenital myasthenic syndromes (CMA) recessively inherited disorders characterized by           |
|                     | muscle weakness.   |
| Pathways:           | Skeletal Muscle Fiber Development  |
| Application Details |  |
| Application Notes:  | IF(IHC-P) 1:50-200   |
|                     | IF(IHC-F) 1:50-200   |
|                     | IF(ICC) 1:50-200   |
| Restrictions:       | For Research Use only  |
| Handling            |  |
| Format:             | Liquid   |
| Concentration:      | 1 μg/μL  |
| Buffer:             | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and      |
|                     | 50 % Glycerol.   |
| Preservative:       | ProClin  |
| Precaution of Use:  | This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be              |
|                     | handled by trained staff only.   |
| Storage:            | -20 °C   |
| Storage Comment:    | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.                |
| Expiry Date:        | 12 months  |